G-CSF (Granulocyte Colony Stimulating Factors) Market Opportunities Are Emerging Beyond Traditional Growth Areas
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
G-CSF (Granulocyte Colony Stimulating Factors) Market Expansion From $9.94 Billion In 2026 To $12.21 Billion In 2030
The granulocyte colony-stimulating factor market has experienced consistent expansion in recent times. In 2025, it was valued at $9.48 billion, and it is projected to reach $9.94 billion by 2026, reflecting a compound annual growth rate of 4.8%. This historical growth has been driven by several factors, including the restricted availability of G-CSF treatments, an increasing incidence of chemotherapy-related neutropenia, a growing number of cancer patients, regulatory endorsements for initial G-CSF therapies, and the uptake of injectable formulations.
The granulocyte colony-stimulating factors (G-CSF) market is projected to experience robust expansion over the next several years. By 2030, its value is anticipated to reach $12.21 billion, reflecting a compound annual growth rate (CAGR) of 5.3%. This forecasted growth is driven by several factors, including the introduction of innovative G-CSF products, the growing availability of biosimilars in developing markets, a heightened use of combination therapies, an increased preference for pre-filled syringe delivery systems, and amplified investment in supportive care and neutropenia management programs. Key developments shaping the market during this period involve a strong uptick in the demand for G-CSF biosimilars, greater utilization of pre-filled syringes and injectable formats, a rising trend of combining G-CSF with other growth factors, an expanded application of these products in oncology and blood disorder treatments, and an improved understanding of neutropenia management alongside supportive care practices.
Download A Free Sample Report For Comprehensive Market Insights:
G-CSF (Granulocyte Colony Stimulating Factors) Market Demand Drivers Creating New Revenue Opportunities
The anticipated expansion of the G-CSF (granulocyte colony stimulating factor) market is being driven forward by the growing incidence of cancer. This disease is defined by the unregulated proliferation and dissemination of abnormal cells, which can impair normal bodily processes and ultimately cause death. The increasing prevalence of cancer results from factors including aging demographics, shifts in lifestyle habits, and environmental exposures that heighten cancer risk. The G-CSF market aligns with this trend by offering growth factors that boost white blood cell production, thereby lowering infection and sepsis risks in cancer patients receiving chemotherapy. As an example, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023—an average of 972 per day—which was 8,605 more than in 2022. Consequently, the rising prevalence of cancer is fueling growth in the G-CSF market.
G-CSF (Granulocyte Colony Stimulating Factors) Market Segment Landscape And Growth Potential
The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –
1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product Form: Tablet, Capsule, Other Product Forms
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
Subsegments:
1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim
2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies
3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim
4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors
G-CSF (Granulocyte Colony Stimulating Factors) Market Trends Driving Strategic Industry Expansion
Key players in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, including the development of dimeric fusion proteins aimed at boosting neutrophil production while minimizing immunogenicity in long-acting G-CSF formulations. This approach involves merging two G-CSF molecules into a single protein structure to prolong its half-life and enhance receptor activation, bypassing the need for PEGylation. A notable example occurred in November 2023, when Evive Biotech Inc., a biopharmaceutical firm based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is designed to shorten the duration of neutropenia and febrile neutropenia in adults receiving cytotoxic chemotherapy. As a modified recombinant G-CSF, Ryzneuta promotes neutrophil generation in the bone marrow, thereby speeding up the restoration of neutrophil levels. Its standout attributes include infrequent dosing, compatibility with various chemotherapy protocols, and a convenient prefilled syringe ready for use. Indicated for preventing chemotherapy-induced neutropenia, mobilizing stem cells, and providing supportive care to immunocompromised patients, it delivers advantages such as reduced injection frequency, enhanced treatment adherence, and superior overall outcomes for individuals.
G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.
Access The Complete G-CSF (Granulocyte Colony Stimulating Factors) Market Report:
G-CSF (Granulocyte Colony Stimulating Factors) Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
